Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

July 6, 2022

Harpoon Therapeutics Expands Leadership Team

May 26, 2022

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

May 12, 2022

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 2, 2022

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

April 12, 2022

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

April 7, 2022

Harpoon Therapeutics Announces Leadership Change

April 7, 2022

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

March 10, 2022

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 7, 2022

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

March 2, 2022

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2023. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations